Recent Company News

• 07:03 AM ET Sep 18, 2025
  

  StreetAccount Summary - European unusual volume traders

• 02:18 AM ET Oct 22, 2025
  

  PureTech Health presents new Phase 2b analyses demonstrating consistent safety and efficacy of deupirfenidone in older patients with IPF (133.4000p, 0)

• 04:04 AM ET Sep 19, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 02:01 AM ET Sep 29, 2025
  

  PureTech Presents New Data from Phase 2B Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF (125.0000p, 0)

• 06:59 AM ET Sep 19, 2025
  

  Healthcare, financials, autos/parts and basic resources best performers; tech, retail and industrials lag:

• 03:28 AM ET Sep 19, 2025
  

  Tang Capital Management LLC announces 3.07% stake in PureTech Health PLC - filing (pre-open) (110.2000p, +3.8)

• 07:10 AM ET Sep 11, 2025
  

  PureTech Health's Seaport Therapeutics advances second therapeutic candidate into clinical development with dosing of first participant in phase 1 study of GlyphAgo (115.2000p, -0.2)